Ligand Pharmaceuticals (LGND) Return on Sales (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 16 years of Return on Sales data on file, last reported at 0.0% in Q1 2026.

• For the quarter ending Q1 2026, Return on Sales rose 1.0% year-over-year to 0.0%; the trailing twelve-month figure through Mar 2026 stood at 0.01% (up 1.0% YoY), and the FY2025 full-year result was 0.0%, changed 0.0% from the prior year.
• Return on Sales retreated to 0.0% in Q1 2026, from 0.01% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.01% in Q3 2025 to a low of 0.01% in Q1 2025.
• A 5-year average of 0.0% and a median of 0.0% in 2022 frame the typical range for Return on Sales.
• Across the five-year window, Return on Sales fell 1 bps in 2024 and grew 1 bps in 2025, its largest moves.
• Tracing LGND's Return on Sales over 5 years: stood at 0.0% in 2022, then surged by 78 bps to 0.0% in 2023, then sank by 5627 bps to 0.01% in 2024, then soared by 203 bps to 0.01% in 2025, then slumped by 134 bps to 0.0% in 2026.
• Business Quant data shows LGND's Return on Sales at 0.0% in Q1 2026, 0.01% in Q4 2025, and 0.01% in Q3 2025.